1) 日本高血圧学会高血圧治療ガイドライン作成委員会(編)2014高血圧治療ガイドライン2014ライフサイエンス出版:7,2014
2) 厚生労働省平成18年国民健康・栄養調査結果の概要,2006 http://www.mhlw.go.jp/houdou/2008/04/h0430-2a.html (Accessed on 22 December, 2016)
3) 厚生労働省国民健康・栄養調査(平成19年),2007 http://www.mhlw.go.jp/bunya/kenkou/eiyou09/index.html (Accessed on 22 December, 2016)
4) 厚生労働省平成23年度国民医療費の概況(平成25年11月14日),2013 http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/11/dl/kekka.pdf (Accessed on 22 December, 2016)
5) 独立行政法人医薬品医療機器総合機構三共株式会社オルメサルタンメドキソミル申請資料概要(平成16年01月29日承認)http://www.pmda.go.jp/drugs/2004/P200400005/index.html (Accessed on 22 December, 2016)
6) 厚生労働省医薬局審査管理課長通知医薬審発第0128001号(平成14年1月28日)「降圧薬の臨床評価に関する原則について」http://www.pmda.go.jp/files/000156598.pdf (Accessed on 22 December, 2016)
7) Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K. Angiotensin II receptor blocker- based therapy in Japanese elderly, high-risk, hypertensive patients. OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group. Am J Med; 125 (10): 981-90, 2012.
8) 厚生省薬務局審査課長通知薬審第592号(平成7年5月24日)「致命的でない疾患に対し長期間の投与が想定される新医薬品の治験段階において安全性を評価するために必要な症例数と投与期間について」http://www.rsihata.com/guidance/pdf/052495YS592E.pdf (Accessed on 22 December, 2016)
9) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use GUIDELINE FOR GOOD CLINICAL PRACTICE, ICH Harmonised Tripartite Guideline, 1996 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (Accessed on 22 December, 2016)
10) Idänpään-Heikkilä JE. WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator. Ann Med; 26(2): 89-94, 1994.
11) 独立行政法人国立病院機構受託研究費算定要領(2008年3月21日登録,2016年4月4日更新) https://www.hosp.go.jp/files/000042751.pdf (Accessed on 22 December, 2016)
12) 厚生労働科学研究費補助金特別研究事業治験コストに係る医療経済学研究平成17.年度総括研究報告書.主任研究者楠岡英雄.平成18(2006)年3月
13) PhRMA “PhRMA Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies” Prepared by Battelle Technology Partnership Practice, Prepared for Pharmaceutical Research and Manufacturers of America (PhRMA), March 2015.
14) Sackett DL, Richardson WS, Rosenberg WMC, Haynes RB. Evidence-based medicine: How to practice and teach EBM. New York: Churchill Livingstone, 1997.
15) Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of Funding and Conclusions in Randomized Drug Trials A Reflection of Treatment Effect or Adverse Events? JAMA; 290(7): 921–8, 2003.
16) Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH. The uncertainty principle and industry-sponsored research. Lancet; 356: 635–8, 2000.
17) Golder S, Loke YK. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol; 66: 767–73, 2008.
18) Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ; 333: 782, 2006.
19) Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC. Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions; BMC Medical Research Methodology, 8: 60, 2008.
20) Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ; 326: 1167-70, 2003.
21) Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ; 326: 1171-73, 2003.
22) Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for- profit organizations: 2000-2005. JAMA; 295: 2270-7, 2006.
23) 厚生労働省厚生労働科学研究における利益相反(ConflictofInterest:COI)の管理に関する指針(平成20年3月31日科発第0331001号厚生科学課長決定)(平成27年4月1日一部改正)(平成29年2月23日一部改正) http://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000152586.pdf (Accessed on 30 October, 2017)
24) Drazen JM, Van Der Weyden MB, Sahni P, Rosenberg J, Marusic A, Laine C, Kotzin S, Horton R, Hébert PC, Haug C, Godlee F, Frizelle FA, de Leeuw PW, DeAngelis CD. Uniform Format for Disclosure of Competing Interests in ICMJE journals. NEJM; 361 (19): 1896-7, 2009.
25) 津谷喜一郎,平盛勝彦,細田瑳一,尾前照雄,佐藤喬俊,宮崎輝彦,黒岩好夫,上嶋健治,深見健一「JAMP study 最終報告」-わが国初の大規模臨床試験:その経緯と教訓-.循環器科; 58(5): 517-30, 2005.
26) 厚生労働省高血圧症治療薬の臨床研究事案に関する検討委員会高血圧症治療薬の臨床研究事案を踏まえた対応及び再発防止策について(報告書)(平成26年4月11日) https://www.mhlw.go.jp/file/05-Shingikai-10801000-Iseikyoku-Soumuka/0000043426.pdf (Accessed on 25 July, 2018)
27) The VA/NIH Acute Renal Failure Trial Network. Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury. N Engl J Med; 359: 7-20, 2008.
28) The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med; 358: 2545-59, 2008.
29) Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JGF, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure. The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial. Circulation; 119: 1616-24, 2009.
30) Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Reduction of Iron Stores and Cardiovascular Outcomes in Patients With Peripheral Arterial Disease. A Randomized Controlled Trial. JAMA; 297(6): 603-10, 2007.
31) Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med; 360(2): 129-39, 2009.
32) Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, Vertrees JE, Shih MC, Holodniy M, Lavori P, for the THINRS Executive Committee and Site Investigators. Effect of Home Testing of International Normalized Ratio on Clinical Events. N Engl J Med; 363: 1608-20, 2010.
33) Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, Lucke JC, Baltz JH, Novitzky D, for the Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group. On-Pump versus Off-Pump Coronary-Artery Bypass Surgery. N Engl J Med; 361: 1827-37, 2009.
34) Bardy GH, Lee KL, Mark DB, Poole JE, Toff WD, Tonkin AM, Smith W, Dorian P, Packer DL, White RD, Longstreth WT Jr, Anderson J, Johnson G, Bischoff E, Yallop JJ, McNulty S, Ray LD, Clapp-Channing NE, Rosenberg Y, Schron EB; HAT Investigators. Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med; 358(17): 1793-804, 2008.
35) Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation; 123(16): 1763-70, 2011.
36) Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT Jr, Matsumura JS, Kohler TR, Lin PH, Jean-Claude JM, Cikrit DF, Swanson KM, Peduzzi PN; Open Versus Endovascular Repair (OVER) Veterans Affairs Cooperative Study Group. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. JAMA; 302(14): 1535-42, 2009.
37) Gao G, Zheng Z, Pi Y, Lu B, Lu J, Hu S. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol; 56(20): 1639-43, 2010.
38) Anderson, ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with Results Reporting at ClinicalTrials.gov. N Engl J Med; 372:1031-9, 2015.
39) 栗山泰,上嶋健治,平盛勝彦,津谷喜一郎.JAMP以降の日本での循環器領域における大規模臨床試験のレビュー.臨床薬理;36(Suppl):S152,2005.
40) UMIN臨床試験登録システム(2005年6月1日新規掲載,2016年4月25日最終更新)http://www.umin.ac.jp/ctr/UMIN-CTR_Yougo.htm (Accessed on 22 December, 2016)
41) Hemminki A, Kellokumpu-Lehtinen PL. Harmful impact of EU clinical trials directive. BMJ; 332: 501-2, 2006.
42) 日本製薬工業協会「企業活動と医療機関等の関係の透明性ガイドライン」(2011年1月19日策定)http://www.jpma.or.jp/tomeisei/aboutguide/ (Accessed on 23 December, 2016)
43) Ross JS, Hill KP, Egilman DS, et al. Documents From Rofecoxib Litigation Related to Rofecoxib: A Case Study of Industry Guest Authorship and Ghostwriting in Publications. JAMA; 299(15): 1800-12, 2008.
44) ノバルティスファーマ株式会社慢性骨髄性白血病治療薬に関する4臨床研究についての社外調査委員会の報告について(2014年5月19日) https://www.novartis.co.jp/about-us/credibility/background-iit/bg-iit-20140519 (Accessed on 30 October, 2017)
45) 帝人ファーマ株式会社市販後調査における弊社MR(医薬情報担当者)の調査票への代筆行為について(2016年5月10日) http://www.teijin-pharma.co.jp/information/2016/20160510.html (Accessed on 30 October, 2017)
46) Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The Costs of Conducting Clinical Research. J Clin Oncol; 21 (22): 4145-50, 2003.
47) 文部科学省・厚生労働省「臨床研究・治験活性化5か年計画2012アクションプラン」(平成24年10月15日) http://www.mhlw.go.jp/topics/bukyoku/isei/chiken/dl/121025_3.pdf (Accessed on 30 October, 2017)
48) 厚生労働省第85回科学技術部会(平成26年7月18日)資料2-3厚生労働科学研究費補助金研究事業の概要(平成25年度報告書) http://www.mhlw.go.jp/file/05-Shingikai-10601000- Daijinkanboukouseikagakuka-Kouseikagakuka/0000051683.pdf (Accessed on 22 December, 2016)
49) National Institutes of Health. DEPARTMENT OF HEALTH AND HUMAN SERVICES, Fiscal Year 2010 Budget Request. http://officeofbudget.od.nih.gov/pdfs/FY10/NIH%20Director's%20Opening%20Statement%205-19- 09%20f.pdf (Accessed on 30 October, 2017)
50) Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Teramoto T, Uchiyama S, Nakamura H; Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study Group. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension; 53(2): 135-41, 2009.
51) Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Technol Assess Health Care; 12(2): 209-37, 1996.
52) Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med; 66(9): 1909-14, 2008.
53) Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]: 8.5 The Cochrane Collaboration's tool for assessing risk of bias. http://handbook-5- 1. cochrane.org/ (Accessed on 30 October, 2017)
54) Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev; 12: MR000033, 2012.
55) Lexchin J. Sponsorship bias in clinical research. Int J Risk Saf Med; 24(4): 233-42, 2012.
56) FDA Clinical Investigators - Disqualification Proceedings http://www.accessdata.fda.gov/scripts/SDA/sdNavigation.cfm?sd=clinicalinvestigatorsdisqualificationproceedin gs&previewMode=true&displayAll=true (Accessed on 22 December, 2016)
57) FDA FDA Debarment List (Drug Product Applications) http://www.fda.gov/ICECI/EnforcementActions/FDADebarmentList/default.htm (Accessed on 22 December, 2016)
58) 厚生労働省 臨床研究法(平成二十九年法律第十六号) https://www.mhlw.go.jp/file/06-Seisakujouhou- 10800000-Iseikyoku/0000163413.pdf (Accessed on 24 July, 2018)
59) 国立研究開発法人 日本医療研究開発機構 AMED による橋渡し研究,臨床研究・治験の推進について https://www.amed.go.jp/content/000004845.pdf (Accessed on 24 July, 2018)